nach oben

Erschienen in:

01.09.2015 | Original Article

Increased CCL17 serum levels are associated with improved survival in advanced melanoma

verfasst von: Benjamin Weide, Nicolas Allgaier, Andreas Hector, Andrea Forschner, Ulrike Leiter, Thomas K. Eigentler, Claus Garbe, Dominik Hartl

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 9/2015

Einloggen, um Zugang zu erhalten

Abstract

Background

Prognostic factors of melanoma patients with distant metastases remain poorly established. This study aimed to compare the prognostic impact of putative serum biomarkers, namely S100B, YKL-40 or CCL17, in stage IV melanoma patients.

Patients and methods

Serum concentrations were analyzed by ELISA. Disease-specific survival of 80 patients according to S100B, YKL-40 or CCL17 and clinical factors were calculated by univariate Kaplan–Meier survival and multivariate analysis.

Results

Low serum levels of S100B, high concentrations of CCL17 and female gender correlated with improved survival. A trend for favorable prognosis was observed for the M categories M1a/b versus M1c according to the AJCC classification. No correlation with survival was evident for YKL-40 serum levels and age. In multivariate analysis, S100B (HR 2.1; p = 0.005) and CCL17 (HR 1.8; p = 0.029) had independent prognostic impact. Patients with a combination of normal S100B and high CCL17 had a high chance for long-term survival, which was 43 % after 3 years.

Conclusion

Serum levels of CCL17 and S100B represent independent prognostic markers for melanoma patients with distant metastases. These biomarkers were more powerful than the M category according to the AJCC classification to indicate overall survival. CCL17 represents a promising biomarker upon immune checkpoint blockade in melanoma.

Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A Jr, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF (2001) Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19(16):3635–3648PubMed

Sirott MN, Bajorin DF, Wong GY, Tao Y, Chapman PB, Templeton MA, Houghton AN (1993) Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis. Cancer 72(10):3091–3098CrossRefPubMed

Eton O, Legha SS, Moon TE, Buzaid AC, Papadopoulos NE, Plager C, Burgess AM, Bedikian AY, Ring S, Dong Q, Glassman AB, Balch CM, Benjamin RS (1998) Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol 16(3):1103–1111PubMed

Manola J, Atkins M, Ibrahim J, Kirkwood J (2000) Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol 18(22):3782–3793PubMed

Pflugfelder A, Kochs C, Blum A, Capellaro M, Czeschik C, Dettenborn T, Dill D, Dippel E, Eigentler T, Feyer P, Follmann M, Frerich B, Ganten MK, Gartner J, Gutzmer R, Hassel J, Hauschild A, Hohenberger P, Hubner J, Kaatz M, Kleeberg UR, Kolbl O, Kortmann RD, Krause-Bergmann A, Kurschat P, Leiter U, Link H, Loquai C, Loser C, Mackensen A, Meier F, Mohr P, Mohrle M, Nashan D, Reske S, Rose C, Sander C, Satzger I, Schiller M, Schlemmer HP, Strittmatter G, Sunderkotter C, Swoboda L, Trefzer U, Voltz R, Vordermark D, Weichenthal M, Werner A, Wesselmann S, Weyergraf AJ, Wick W, Garbe C, Schadendorf D (2013) Malignant melanoma S3-guideline “diagnosis, therapy and follow-up of melanoma”. J Dtsch Dermatol Ges 11 (Suppl 6):1–116, 111–126. doi:10.1111/ddg.12113_suppl

Mocellin S, Zavagno G, Nitti D (2008) The prognostic value of serum S100B in patients with cutaneous melanoma: a meta-analysis. Int J Cancer 123(10):2370–2376. doi:10.1002/ijc.23794 CrossRefPubMed

Weide B, Richter S, Buttner P, Leiter U, Forschner A, Bauer J, Held L, Eigentler TK, Meier F, Garbe C (2013) Serum S100B, lactate dehydrogenase and brain metastasis are prognostic factors in patients with distant melanoma metastasis and systemic therapy. PLoS ONE 8(11):e81624. doi:10.1371/journal.pone.0081624 PubMedCentralCrossRefPubMed

Weide B, Elsasser M, Buttner P, Pflugfelder A, Leiter U, Eigentler TK, Bauer J, Witte M, Meier F, Garbe C (2012) Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis. Br J Cancer 107(3):422–428. doi:10.1038/bjc.2012.306 PubMedCentralCrossRefPubMed

Real E, Kaiser A, Raposo G, Amara A, Nardin A, Trautmann A, Donnadieu E (2004) Immature dendritic cells (DCs) use chemokines and intercellular adhesion molecule (ICAM)-1, but not DC-specific ICAM-3-grabbing nonintegrin, to stimulate CD4+ T cells in the absence of exogenous antigen. J Immunol 173(1):50–60CrossRefPubMed

10.

Semmling V, Lukacs-Kornek V, Thaiss CA, Quast T, Hochheiser K, Panzer U, Rossjohn J, Perlmutter P, Cao J, Godfrey DI, Savage PB, Knolle PA, Kolanus W, Forster I, Kurts C (2010) Alternative cross-priming through CCL17-CCR4-mediated attraction of CTLs toward NKT cell-licensed DCs. Nat Immunol 11(4):313–320CrossRefPubMed

11.

Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, Staehler M, Brugger W, Dietrich PY, Mendrzyk R, Hilf N, Schoor O, Fritsche J, Mahr A, Maurer D, Vass V, Trautwein C, Lewandrowski P, Flohr C, Pohla H, Stanczak JJ, Bronte V, Mandruzzato S, Biedermann T, Pawelec G, Derhovanessian E, Yamagishi H, Miki T, Hongo F, Takaha N, Hirakawa K, Tanaka H, Stevanovic S, Frisch J, Mayer-Mokler A, Kirner A, Rammensee HG, Reinhardt C, Singh-Jasuja H (2012) Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 18(8):1254–1261. doi:10.1038/nm.2883 CrossRefPubMed

12.

Cornforth AN, Lee GJ, Fowler AW, Carbonell DJ, Dillman RO (2009) Increases in serum TARC/CCL17 levels are associated with progression-free survival in advanced melanoma patients in response to dendritic cell-based immunotherapy. J Clin Immunol 29(5):657–664. doi:10.1007/s10875-009-9299-3 CrossRefPubMed

13.

Schmidt H, Johansen JS, Gehl J, Geertsen PF, Fode K, von der Maase H (2006) Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma. Cancer 106(5):1130–1139CrossRefPubMed

14.

Egberts F, Kotthoff EM, Gerdes S, Egberts JH, Weichenthal M, Hauschild A (2012) Comparative study of YKL-40, S-100B and LDH as monitoring tools for stage IV melanoma. Eur J Cancer 48(5):695–702CrossRefPubMed

15.

Lasithiotakis KG, Leiter U, Gorkievicz R, Eigentler T, Breuninger H, Metzler G, Strobel W, Garbe C (2006) The incidence and mortality of cutaneous melanoma in Southern Germany: trends by anatomic site and pathologic characteristics, 1976 to 2003. Cancer 107(6):1331–1339CrossRefPubMed

16.

Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC Jr, Morton DL, Ross MI, Sober AJ, Sondak VK (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27(36):6199–6206. doi:10.1200/JCO.2009.23.4799 PubMedCentralCrossRefPubMed

17.

Volck B, Price PA, Johansen JS, Sorensen O, Benfield TL, Nielsen HJ, Calafat J, Borregaard N (1998) YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils. Proc Assoc Am Physicians 110(4):351–360PubMed

18.

Lee CG, Hartl D, Lee GR, Koller B, Matsuura H, Da Silva CA, Sohn MH, Cohn L, Homer RJ, Kozhich AA, Humbles A, Kearley J, Coyle A, Chupp G, Reed J, Flavell RA, Elias JA (2009) Role of breast regression protein 39 (BRP-39)/chitinase 3-like-1 in Th2 and IL-13-induced tissue responses and apoptosis. J Exp Med 206(5):1149–1166. doi:10.1084/jem.20081271 PubMedCentralCrossRefPubMed

19.

Recklies AD, White C, Ling H (2002) The chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B-mediated signalling pathways. Biochem J 365(Pt 1):119–126. doi:10.1042/BJ20020075 PubMedCentralCrossRefPubMed

20.

Renkema GH, Boot RG, Au FL, Donker-Koopman WE, Strijland A, Muijsers AO, Hrebicek M, Aerts JM (1998) Chitotriosidase, a chitinase, and the 39-kDa human cartilage glycoprotein, a chitin-binding lectin, are homologues of family 18 glycosyl hydrolases secreted by human macrophages. Eur J Biochem 251(1–2):504–509CrossRefPubMed

21.

Jensen BV, Johansen JS, Price PA (2003) High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer. Clin Cancer Res 9(12):4423–4434PubMed

22.

Johansen JS, Drivsholm L, Price PA, Christensen IJ (2004) High serum YKL-40 level in patients with small cell lung cancer is related to early death. Lung Cancer 46(3):333–340. doi:10.1016/j.lungcan.2004.05.010 CrossRefPubMed

23.

Cintin C, Johansen JS, Christensen IJ, Price PA, Sorensen S, Nielsen HJ (2002) High serum YKL-40 level after surgery for colorectal carcinoma is related to short survival. Cancer 95(2):267–274CrossRefPubMed

24.

Schmidt H, Johansen JS, Sjoegren P, Christensen IJ, Sorensen BS, Fode K, Larsen J, von der Maase H (2006) Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma. J Clin Oncol 24(5):798–804CrossRefPubMed

25.

Smit LH, Korse CM, Hart AA, Bonfrer JM, Haanen JB, Kerst JM, Nieweg OE, de Gast GC (2005) Normal values of serum S-100B predict prolonged survival for stage IV melanoma patients. Eur J Cancer 41(3):386–392. doi:10.1016/j.ejca.2004.10.019 CrossRefPubMed

26.

Egberts F, Pollex A, Egberts JH, Kaehler KC, Weichenthal M, Hauschild A (2008) Long-term survival analysis in metastatic melanoma: serum S100B is an independent prognostic marker and superior to LDH. Onkologie 31(7):380–384CrossRefPubMed

27.

Martenson ED, Hansson LO, Nilsson B, von Schoultz E, Brahme EM, Ringborg U, Hansson J (2001) Serum S-100B protein as a prognostic marker in malignant cutaneous melanoma. J Clin Oncol 19(3):824–831PubMed

28.

Donato R (2001) S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol 33(7):637–668CrossRefPubMed

29.

Hergovich A, Stegert MR, Schmitz D, Hemmings BA (2006) NDR kinases regulate essential cell processes from yeast to humans. Nat Rev Mol Cell Biol 7(4):253–264. doi:10.1038/nrm1891 CrossRefPubMed

30.

Romagnani S (2002) Cytokines and chemoattractants in allergic inflammation. Mol Immunol 38(12–13):881–885CrossRefPubMed

31.

Zabel BA, Rott A, Butcher EC (2015) Leukocyte chemoattractant receptors in human disease pathogenesis. Annu Rev Pathol 10:51–81. doi:10.1146/annurev-pathol-012513-104640 CrossRefPubMed

32.

Griffith JW, Sokol CL, Luster AD (2014) Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu Rev Immunol 32:659–702. doi:10.1146/annurev-immunol-032713-120145 CrossRefPubMed

33.

Henry CJ, Ornelles DA, Mitchell LM, Brzoza-Lewis KL, Hiltbold EM (2008) IL-12 produced by dendritic cells augments CD8+ T cell activation through the production of the chemokines CCL1 and CCL17. J Immunol 181(12):8576–8584PubMedCentralCrossRefPubMed

34.

Inoue H, Iga M, Xin M, Asahi S, Nakamura T, Kurita R, Nakayama M, Nakazaki Y, Takayama K, Nakanishi Y, Tani K (2008) TARC and RANTES enhance antitumor immunity induced by the GM-CSF-transduced tumor vaccine in a mouse tumor model. Cancer Immunol Immunother 57(9):1399–1411. doi:10.1007/s00262-008-0476-7 CrossRefPubMed

35.

Biragyn A, Bodogai M, Olkhanud PB, Denny-Brown SR, Puri N, Ayukawa K, Kanegasaki S, Hogaboam CM, Wejksza K, Lee-Chang C (2013) Inhibition of lung metastasis by chemokine CCL17-mediated in vivo silencing of genes in CCR4+ Tregs. J Immunother 36(4):258–267. doi:10.1097/CJI.0b013e318294357c PubMedCentralCrossRefPubMed

36.

Sugiyama D, Nishikawa H, Maeda Y, Nishioka M, Tanemura A, Katayama I, Ezoe S, Kanakura Y, Sato E, Fukumori Y, Karbach J, Jager E, Sakaguchi S (2013) Anti-CCR4 mAb selectively depletes effector-type FoxP3+ CD4+ regulatory T cells, evoking antitumor immune responses in humans. Proc Natl Acad Sci USA 110(44):17945–17950. doi:10.1073/pnas.1316796110 PubMedCentralCrossRefPubMed

37.

Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, Wunderlich J, Restifo NP, Thomasian A, Downey SG, Smith FO, Klapper J, Morton K, Laurencot C, White DE, Rosenberg SA (2008) Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 26(32):5233–5239. doi:10.1200/JCO.2008.16.5449 PubMedCentralCrossRefPubMed

38.

Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711–723. doi:10.1056/NEJMoa1003466 PubMedCentralCrossRefPubMed

39.

Robert C, Thomas L, Bondarenko I, O’Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH Jr, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364(26):2517–2526. doi:10.1056/NEJMoa1104621 CrossRefPubMed

40.

Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369(2):134–144. doi:10.1056/NEJMoa1305133 PubMedCentralCrossRefPubMed

41.

Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366(26):2455–2465. doi:10.1056/NEJMoa1200694 PubMedCentralCrossRefPubMed

42.

Ji RR, Chasalow SD, Wang L, Hamid O, Schmidt H, Cogswell J, Alaparthy S, Berman D, Jure-Kunkel M, Siemers NO, Jackson JR, Shahabi V (2012) An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother 61(7):1019–1031. doi:10.1007/s00262-011-1172-6 CrossRefPubMed

43.

Ascierto PA, Kalos M, Schaer DA, Callahan MK, Wolchok JD (2013) Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types. Clin Cancer Res 19(5):1009–1020. doi:10.1158/1078-0432.CCR-12-2982 CrossRefPubMed

Titel: Increased CCL17 serum levels are associated with improved survival in advanced melanoma
verfasst von: Benjamin Weide
Nicolas Allgaier
Andreas Hector
Andrea Forschner
Ulrike Leiter
Thomas K. Eigentler
Claus Garbe
Dominik Hartl
Publikationsdatum: 01.09.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 9/2015
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-015-1714-4

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Increased CCL17 serum levels are associated with improved survival in advanced melanoma

Abstract

Background

Patients and methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Background

Patients and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2015

Local and systemic XAGE-1b-specific immunity in patients with lung adenocarcinoma

Modulating the innate immune activity in murine tumor microenvironment by a combination of inducer molecules attached to microparticles

Immune checkpoint targeting as anti-cancer immunotherapy: promises, questions, challenges and the need for predictive biomarkers at ASCO 2015

Phase I trial of thymidylate synthase poly-epitope peptide (TSPP) vaccine in advanced cancer patients

A pilot study in prostate cancer patients treated with the AE37 Ii-key-HER-2/neu polypeptide vaccine suggests that HLA-A*24 and HLA-DRB1*11 alleles may be prognostic and predictive biomarkers for clinical benefit

Immune biomarkers are more accurate in prediction of survival in ulcerated than in non-ulcerated primary melanomas

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

A pilot study in prostate cancer patients treated with the AE37 Ii-key-HER-2/neu polypeptide vaccine suggests that HLA-A24 and HLA-DRB111 alleles may be prognostic and predictive biomarkers for clinical benefit